ClinicalTrials.gg
CompletedNCT01294462Updated Jun 27, 2014Results posted

Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

A Phase 3 interventional study of Ticagrelor and Clopidogrel in Acute Coronary Syndrome and Percutaneous Coronary Intervention, sponsored by AstraZeneca. Completed at 94 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
801
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.

Enrollment
18th of 67
801 · median 120
Started
2011
with 1 other
Phase 3
16 of 67
1 open now
Registered
3rd of 67
by date
Lead sponsor
8 of 67
AstraZeneca

Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 18th largest by enrollment, is one of 2 that started in 2011, is one of 16 in phase 3, and was the 3rd registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing ticagrelor in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese patients with acute coronary syndrome and a planned percutaneous coronary intervention (PCI).

03

Conditions studied

  • Acute Coronary Syndrome
  • Percutaneous Coronary Intervention

Keywords

  • acute coronary syndrome
  • coronary disease
  • coronary artery disease
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed
  • Index event of non-ST or ST segment elevation ACS

Exclusion criteria

Exclusion Criteria:

  • Index event is an acute complication of percutaneous coronary intervention
  • Patient has undergone Percutaneous Coronary Intervention (PCI) after the index event before the first dose of study treatment
  • Oral anticoagulation therapy that cannot be stopped
  • The conditions associated with increased risk of bradycardiac events
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
801 participants (actual)

Study arms

  • Experimental
    1

    Ticagrelor (AZD6140)

    Drug: Ticagrelor · Drug: Acetylsalicylic acid ASA

  • Active comparator
    2

    Clopidogrel

    Drug: Clopidogrel · Drug: Acetylsalicylic acid ASA

Interventions

06

What researchers measure

Primary outcomes

  1. Major Bleeding

    Time to first occurrence of any major bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.

    Time frame: Ongoing up to12 months

  2. Major Adverse Cardiac Events (MACE)

    Time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.

    Time frame: Ongoing up to 12 months

Secondary outcomes

  1. Major and Minor Bleeding

    Time to first occurrence of any major or minor bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.

    Time frame: Ongoing up to12 months

  2. Composite of All-cause Mortality, MI or Stroke

    Time to first occurrence of any event from the composite of death from any causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.

    Time frame: Ongoing up to 12 months

07

Results

Posted May 2, 2014

Participant flow

In total, 817 patients were enrolled from 3 countries (Japan, South Korea and Taiwan). Of the randomised patients, most patients were Japanese (723 \[90.3%\]). The first patient was enrolled on 28 February 2010 and the last patient completed the study on 31 July 2012.

Participant flow — Overall Study
MilestoneTicagrelor (AZD6140)Clopidogrel
Started401400
Received randomized treatment387380
Completed335337
Not completed6663
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject6563

Outcome measures

PrimaryMajor Bleeding

Time to first occurrence of any major bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.

Time frame:
Ongoing up to12 months
Reported as:
Number · Percent probability
Major Bleeding
Percent probabilityTicagrelor (AZD6140)Clopidogrel
Major Bleeding11.28.4
Statistical analysis
  • Ticagrelor (AZD6140) vs Clopidogrel · Regression, Cox · Hazard ratio (hr): 1.54 · 95% CI 0.94 to 2.53Ticagrelor/Placebo
PrimaryMajor Adverse Cardiac Events (MACE)

Time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.

Time frame:
Ongoing up to 12 months
Reported as:
Number · Percent probability
Major Adverse Cardiac Events (MACE)
Percent probabilityTicagrelor (AZD6140)Clopidogrel
Major Adverse Cardiac Events (MACE)10.28.1
Statistical analysis
  • Ticagrelor (AZD6140) vs Clopidogrel · Regression, Cox · Hazard ratio (hr): 1.47 · 95% CI 0.88 to 2.44Ticagrelor/Placebo
SecondaryMajor and Minor Bleeding

Time to first occurrence of any major or minor bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)). 1-year event rate (%) estimated via Kaplan-Meier method.

Time frame:
Ongoing up to12 months
Reported as:
Number · Percent probability
Major and Minor Bleeding
Percent probabilityTicagrelor (AZD6140)Clopidogrel
Major and Minor Bleeding26.816.2
Statistical analysis
  • Ticagrelor (AZD6140) vs Clopidogrel · Regression, Cox · Hazard ratio (hr): 1.72 · 95% CI 1.23 to 2.40Ticagrelor/Placebo
SecondaryComposite of All-cause Mortality, MI or Stroke

Time to first occurrence of any event from the composite of death from any causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC). 1-year event rate (%) estimated via Kaplan-Meier method.

Time frame:
Ongoing up to 12 months
Reported as:
Number · Percent probability
Composite of All-cause Mortality, MI or Stroke
Percent probabilityTicagrelor (AZD6140)Clopidogrel
Composite of All-cause Mortality, MI or Stroke10.58.1
Statistical analysis
  • Ticagrelor (AZD6140) vs Clopidogrel · Regression, Cox · Hazard ratio (hr): 1.51 · 95% CI 0.91 to 2.50Ticagrelor/Placebo

Adverse events

Collected over Approximately 6 months to 1 year.. Non-serious events are listed at a 1.8% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor (AZD6140)—92/387 (23.8%)327/387 (84.5%)
Clopidogrel—112/380 (29.5%)337/380 (88.7%)
Most frequent serious events
Showing 10 of 115
Most frequent serious events
EventTicagrelor (AZD6140)Clopidogrel
Coronary artery stenosisCardiac disorders36/38747/380
In-stent coronary artery restenosisInjury, poisoning and procedural complications11/38710/380
Angina pectorisCardiac disorders5/3879/380
Coronary artery restenosisInjury, poisoning and procedural complications6/3878/380
Angina unstableCardiac disorders4/3875/380
Thrombosis in deviceGeneral disorders2/3874/380
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/3874/380
Acute myocardial infarctionCardiac disorders4/3872/380
Cerebral infarctionNervous system disorders4/3872/380
Myocardial ischaemiaCardiac disorders2/3873/380
Most frequent other events
Showing 10 of 52
Most frequent other events
EventTicagrelor (AZD6140)Clopidogrel
NasopharyngitisInfections and infestations55/38759/380
ConstipationGastrointestinal disorders59/38755/380
HeadacheNervous system disorders33/38757/380
InsomniaPsychiatric disorders58/38749/380
PyrexiaGeneral disorders56/38751/380
Back painMusculoskeletal and connective tissue disorders44/38746/380
Myocardial infarcionCardiac disorders35/38723/380
VomitingGastrointestinal disorders21/38727/380
HypertensionVascular disorders23/38727/380
NauseaGastrointestinal disorders21/38726/380

Baseline characteristics

One discontinued patient (due to withdrawal of consent) in Ticagrelor (AZD6140) group did not agree to disclose any data. Thus the number of baseline participants in Ticagrelor (AZD6140) group is 400 instead of 401 that is the number of participants who started the first period.

Age, Continuous
Age, Continuous(Years)Ticagrelor (AZD6140)ClopidogrelTotal
Mean67 ± 1266 ± 1167 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Ticagrelor (AZD6140)ClopidogrelTotal
Female9593188
Male305307612
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor (AZD6140)ClopidogrelTotal
Chinese161935
Japanese361360721
Korean232144
08

Study locations

94 sites
  • Research Site
    Ichinomiya-shi, Aichi, Japan
  • Research Site
    Nagoya-shi, Aichi, Japan
  • Research Site
    Okazaki-shi, Aichi, Japan
  • Research Site
    Toyohashi-shi, Aichi, Japan
  • Research Site
    Toyota-shi, Aichi, Japan
  • Research Site
    Akita-shi, Akita, Japan
  • Research Site
    Ichihara-shi, Chiba, Japan
  • Research Site
    Kamogawa-shi, Chiba, Japan
  • Research Site
    Kisarazu-shi, Chiba, Japan
  • Research Site
    Matsuyama, Ehime, Japan
  • Research Site
    Fukui-shi, Fukui, Japan
  • Research Site
    Fukuoka-shi, Fukuoka, Japan
  • Research Site
    Kasuya-gun, Fukuoka, Japan
  • Research Site
    Kurume, Fukuoka, Japan
  • Research Site
    Gifu-shi, Gifu, Japan
  • Research Site
    Isesaki, Gunma, Japan
  • Research Site
    Maebashi, Gunma, Japan
  • Research Site
    Takasaki-shi, Gunma, Japan
  • Research Site
    Kure, Hiroshima, Japan
  • Research Site
    Sapporo-shi, Hokkaido, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Akashi-shi, Hyogo, Japan
  • Research Site
    Amagasaki-shi, Hyogo, Japan
  • Research Site
    Kawanishi-shi, Hyogo, Japan
  • Research Site
    Kobe-shi, Hyogo, Japan
  • Research Site
    Kobe, Hyogo, Japan
  • Research Site
    Nishinomiya, Hyogo, Japan
  • Research Site
    Takarazuka-shi, Hyogo, Japan
  • Research Site
    Higashiibaragi-gun, Ibaragi, Japan
  • Research Site
    Sashima-gun, Ibaragi, Japan
  • Research Site
    Hakusan-shi, Ishikawa, Japan
  • Research Site
    Kanazawa-shi, Ishikawa, Japan
  • Research Site
    Kanazawa, Ishikawa, Japan
  • Research Site
    Sakaide-shi, Kagawa, Japan
  • Research Site
    Atsugi-shi, Kanagawa, Japan
  • Research Site
    Isehara, Kanagawa, Japan
  • Research Site
    Kamakura-shi, Kanagawa, Japan
  • Research Site
    Kawasaki-shi, Kanagawa, Japan
  • Research Site
    Sagamihara-shi, Kanagawa, Japan
  • Research Site
    Yamato-shi, Kanagawa, Japan
  • Research Site
    Yokohama-shi, Kanagawa, Japan
  • Research Site
    Nankoku-shi, Kochi, Japan
  • Research Site
    Kumamoto-shi, Kumamoto, Japan
  • Research Site
    Yatsushiro-city, Kumamoto, Japan
  • Research Site
    Kyoto-shi, Kyoto, Japan
  • Research Site
    Sendai-shi, Miyagi, Japan
  • Research Site
    Azumino-shi, Nagano, Japan
  • Research Site
    Ueda-shi, Nagano, Japan
  • Research Site
    Nagasaki-shi, Nagasaki, Japan
  • Research Site
    Kurashiki, Okayama, Japan
  • Research Site
    Okayama-shi, Okayama, Japan
  • Research Site
    Hirakata, Osaka, Japan
  • Research Site
    Kawachinagano-shi, Osaka, Japan
  • Research Site
    Osaka-shi, Osaka, Japan
  • Research Site
    Sakai-shi, Osaka, Japan
  • Research Site
    Saga-shi, Saga, Japan
  • Research Site
    Ageo-shi, Saitama, Japan
  • Research Site
    Hidaka, Saitama, Japan
  • Research Site
    Sayama-shi, Saitama, Japan
  • Research Site
    Kusatsu-shi, Shiga, Japan
  • Research Site
    Moriyama, Shiga, Japan
  • Research Site
    Matsue, Shimane, Japan
  • Research Site
    Hamamatsu-shi, Shizuoka, Japan
  • Research Site
    Izunokuni, Shizuoka, Japan
  • Research Site
    Shimada-shi, Shizuoka, Japan
  • Research Site
    Sunto-gun, Shizuoka, Japan
  • Research Site
    Komatsushima-shi, Tokushima, Japan
  • Research Site
    Tokushima-shi, Tokushima, Japan
  • Research Site
    Adachi-ku, Tokyo, Japan
  • Research Site
    Bunkyo-ku, Tokyo, Japan
  • Research Site
    Bunkyo, Tokyo, Japan
  • Research Site
    Chiyoda-ku, Tokyo, Japan
  • Research Site
    Itabashi-ku, Tokyo, Japan
  • Research Site
    Meguro, Tokyo, Japan
  • Research Site
    Ome-shi, Tokyo, Japan
  • Research Site
    Shinagawa-ku, Tokyo, Japan
  • Research Site
    Shinjuku, Tokyo, Japan
  • Research Site
    Suginami-ku, Tokyo, Japan
  • Research Site
    Tanabe-shi, Wakayama, Japan
  • Research Site
    Chuo-shi, Yamanashi, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Gifu, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Saga, Japan
  • Research Site
    Wakayama, Japan
  • Research Site
    Cheonan, Chungcheongnam-do, Korea, Republic of
  • Research Site
    Daejeon, Korea, Republic of
  • Research Site
    Incheon, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Niao-song-shiang, Kaohsiung, Taiwan
  • Research Site
    Kweishan Shiang, Taoyuan Hsien, Taiwan
  • Research Site
    Taichung, Taiwan
  • Research Site
    Taipei, Taiwan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 10 months after primary completion. A results delay was requested in Feb 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2011
First posted
Feb 11, 2011
Start
Feb 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results delay requested
Feb 23, 2011
Results first posted
May 2, 2014
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01294462
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 11, 2011
Start date
Feb 2011
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
May 2, 2014
Last update
Jun 27, 2014

Study contacts

Judith Hsia, MD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion